These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 17592007

  • 1. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
    Cochran BG, Sowinski KM, Fausel C, Overholser BR.
    Am J Health Syst Pharm; 2007 Jul 01; 64(13):1410-4. PubMed ID: 17592007
    [Abstract] [Full Text] [Related]

  • 2. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
    Najari Z, Rusho WJ.
    Am J Health Syst Pharm; 1997 Jan 15; 54(2):181-4. PubMed ID: 9117807
    [Abstract] [Full Text] [Related]

  • 3. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.
    Berti AD, Hutson PR, Schulz LT, Webb AP, Rose WE.
    Am J Health Syst Pharm; 2015 Mar 01; 72(5):390-5. PubMed ID: 25694414
    [Abstract] [Full Text] [Related]

  • 4. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
    Am J Health Syst Pharm; 2014 Aug 01; 71(15):1288-91. PubMed ID: 25027536
    [Abstract] [Full Text] [Related]

  • 5. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ, Demmon SL, Boelk DA, Payne CA, Effron MB, Rajagopalan N, Williams MD, Beck GM, Gopalrathnam G.
    Am J Health Syst Pharm; 2004 Dec 15; 61(24):2664-71. PubMed ID: 15646701
    [Abstract] [Full Text] [Related]

  • 6. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
    Patel K, Hursting MJ.
    Am J Health Syst Pharm; 2005 Jul 01; 62(13):1381-4. PubMed ID: 15972381
    [Abstract] [Full Text] [Related]

  • 7. Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid.
    Anaizi NH, Swenson CF, Dentinger PJ.
    Am J Health Syst Pharm; 1998 May 01; 55(9):926-9. PubMed ID: 9588251
    [Abstract] [Full Text] [Related]

  • 8. Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride.
    Johnson CE, Truong NM.
    J Am Pharm Assoc (Wash); 1999 May 01; 39(4):505-8. PubMed ID: 10467814
    [Abstract] [Full Text] [Related]

  • 9. Impairment of mycophenolate mofetil absorption by calcium polycarbophil.
    Kato R, Ooi K, Ikura-Mori M, Tsuchishita Y, Hashimoto H, Yoshimura H, Uenishi K, Kawai M, Tanaka K, Ueno K.
    J Clin Pharmacol; 2002 Nov 01; 42(11):1275-80. PubMed ID: 12412828
    [Abstract] [Full Text] [Related]

  • 10. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
    Woloschuk DM, Wermeling JR, Pruemer JM.
    Am J Hosp Pharm; 1991 Oct 01; 48(10):2158-60. PubMed ID: 1781472
    [Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration.
    Waller JR, Brook NR, Bicknell GR, Murphy GJ, Nicholson ML.
    Transplant Proc; 2005 Oct 01; 37(1):164-6. PubMed ID: 15808582
    [Abstract] [Full Text] [Related]

  • 12. Stability of mycophenolate mofetil in an extemporaneously compounded sugar-free oral liquid.
    Swenson CF, Dentinger PJ, Anaizi NH.
    Am J Health Syst Pharm; 1999 Nov 01; 56(21):2224-6. PubMed ID: 10565702
    [No Abstract] [Full Text] [Related]

  • 13. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A, Mann HJ.
    Am J Health Syst Pharm; 2010 Oct 01; 67(19):1640-4. PubMed ID: 20852166
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B, Klepetko W.
    J Thorac Cardiovasc Surg; 2003 Apr 01; 125(4):891-900. PubMed ID: 12698153
    [Abstract] [Full Text] [Related]

  • 15. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
    Kupie TC, Trusley C, Ben M, Trissel LA.
    Am J Health Syst Pharm; 2008 Sep 15; 65(18):1735-59. PubMed ID: 18769000
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE, Nicholls AJ, Kamm BR.
    Clin Pharmacokinet; 1998 Jun 15; 34(6):429-55. PubMed ID: 9646007
    [Abstract] [Full Text] [Related]

  • 18. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.
    So W, Kim L, Thabit AK, Nicolau DP, Kuti JL.
    Am J Health Syst Pharm; 2017 Jan 01; 74(1):e55-e63. PubMed ID: 28007722
    [Abstract] [Full Text] [Related]

  • 19. Stability of mycophenolate mofetil as an extemporaneous suspension.
    Venkataramanan R, McCombs JR, Zuckerman S, McGhee B, Pisupati J, Dice JE.
    Ann Pharmacother; 1998 Jan 01; 32(7-8):755-7. PubMed ID: 9681090
    [Abstract] [Full Text] [Related]

  • 20. Mutagenic and cytotoxic effects of immunosuppressive drugs on human lymphocyte cultures.
    Oliveira VD, Zankl H, Rath T.
    Exp Clin Transplant; 2004 Dec 01; 2(2):273-9. PubMed ID: 15859941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.